Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

LUPIN-Approval

More Like This

Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)

PR Newswire associated0

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform

PR Newswire associated0

Orphalan becomes the first European company to enter in China's Wilson Disease market

PR Newswire associated0

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform

PR Newswire associated0

Lupin Completes Acquisition of VISUfarma

PR Newswire associated0

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines